This application supports a specified investigation or treatment-access use of a drug in the United States. It is separate from permission to market the product.
An Investigational New Drug application contains nonclinical, manufacturing and clinical-protocol information for defined investigational use. Becoming effective does not establish that the product benefits a person or is approved for marketing, and a clinical hold can prevent use. A New Drug Application or Biologics License Application instead requests marketing authorization. Submission, acceptance for filing, an application becoming effective and a marketing decision are different events. The applicable route and product version matter.
Shares Fast Track and RMAT designations, Right to Try Act 2018 and state right-to-try laws, Expanded access (compassionate use).
Shares Label, indication and label expansion, Fast Track and RMAT designations, BLA / NDA / MAA (marketing applications) and PDUFA dates.
Shares Right to Try Act 2018 and state right-to-try laws, Expanded access (compassionate use).
Shares Label, indication and label expansion, First-in-human (FIH) trial, BLA / NDA / MAA (marketing applications) and PDUFA dates, Trial protocol and statistical analysis plan.
Shares Fast Track and RMAT designations, Expanded access (compassionate use), BLA / NDA / MAA (marketing applications) and PDUFA dates.
Shares Label, indication and label expansion, Fast Track and RMAT designations.
Shares Fast Track and RMAT designations, BLA / NDA / MAA (marketing applications) and PDUFA dates.
Shares Clinical trial search, site verification and screening, Trial protocol and statistical analysis plan.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/